Optimal dose-finding study of bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3797-3802

  Koizumi, Wasaburo ^a   Tanabe, Satoshi ^a   Higuchi, Katsuhiko ^a   Sasaki, Toru ^a   Nakayama, Shosuke ^a   Nakatani, Kento ^a   Nishimura, Ken ^a   Shimoda, Takuya ^a   Azuma, Mizutomo ^a   Ishido, Kenji ^a   Saigenji, Katsunori ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Disease control rate; Neuropathy; Patient convenience; Second line chemotherapy

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE CALCULATION; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUROPATHY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RECURRENT CANCER; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; RECURRENCE;

EID: 33750723425     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Nomura K: Age-adjusted death rates of malignant neoplasms by site, sex and calendar year. Cancer Statistics in Japan, 2005. Foundation for Promotion of Cancer Research, p. 12-14, 2005.
2. Ohtsu A, Boku N, Tamura F et al: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21(4): 416-419, 1998.
3. Yamada Y, Shirao K, Ohtsu A et al: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against palicitaxel-associated hypersensivity reactions. Ann Oncol 12: 1133-1137, 2001.
4. Yamaguchi K, Tada M, Horikoshi N et al: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 5: 90-95, 2002.
5. Rosenberg P, Andersson H, Boman K et al: A Randomized multicenter study of single agent paclitaxel (TAXOL) given weekly versus every three weeks to patients (pts) with ovarian cancer (OC) previously treated with platinum therapy. Proc ASCO 18: 368a, 1999.
6. Emi Y, Kakeji Y, Baba H et al: Weekly paclitaxel therapy as second-line therapy for advanced, recurrent stomach cancer. Jpn J Cancer Clin 50(4): 277-281, 2004.
7. Wani MC, Taylor HL, Wall ME et al: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
8. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
9. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990.
10. Noda K, Ikeda M, Kudo R et al: Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion. Gan To Kagaku Ryoho 23(3): 317-325, 1996.
11. Sekine I, Nishiwaki Y, Watanabe K et al: Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 2(6): 941-945, 1996.
12. Yoneda S, Nishiwaki Y, Niitani H et al: Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group. Gan To Kagaku Ryoho. 23(6): 695-701, 1996.
13. Furuse K, Naka N, Takada M et al: Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology 54(4): 298-303, 1997.
14. Ito Y, Horikoshi N, Watanabe T et al: Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group. Invest New Drugs 16(2): 183-190, 1998.
15. Seidman AD, Hudis CA, Albanel J et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16(10): 3353-3361, 1998.
16. Arai T, Hamaguchi T, Shirao K et al: Weekly Paclitaxel (PTX) in patients with heavily treated advanced gastric cancer (AGC). Jpn J Cancer Clin 49(7): 621-625, 2003.